Remove 2014 Remove Physicians Remove Safety
article thumbnail

PhRMA lies to protect pharma profits

World of DTC Marketing

Data were mainly accessible for smaller firms, products in some therapeutic regions, orphan drugs, first-in-class drugs, therapeutic agents that received accelerated approval, and products between 2014 and 2018. The most telling data on a disconnect between drug prices and research costs has received almost no public attention.

Pharma 255
article thumbnail

Collaboration with Janssen and Eli Lilly to address lack of paediatric medications

Pharmaceutical Technology

In recent years, with the advent of biologics and novel therapeutic targets such as anti-TNF, anti-interleukin, and anti-integrin, there has been a steady increase in the number of agents approved to treat inflammatory bowel diseases (IBD), which has provided physicians with an increasing number of options to treat Crohn’s disease (CD).

Medical 59
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Relief for Amylyx as FDA clears controversial ALS drug Relyvrio

pharmaphorum

” However, it added that the limited efficacy of the two approved therapies for ALS – Radicava and oral riluzole – plus the apparent safety of Relyvrio means that “this level of uncertainty is acceptable in this instance and consideration of these results in the context of regulatory flexibility is appropriate.”

FDA 84
article thumbnail

Competition is on the horizon for costly narcolepsy treatments

pharmaphorum

Both the physician and the patient have to be registered and the drugs can only come from a primary source through limited distribution. Tentative approval means Lumryz has satisfied all the FDA requirements for efficacy, safety, and quality standards, but it can’t be fully approved until a patent or other exclusivity expires.

article thumbnail

The future of medical cannabis development in Europe

European Pharmaceutical Review

In many European countries physicians can now prescribe medical cannabis for an array of chronic health conditions, including chronic pain, mental health disorders and neurological conditions. An observational study of safety and clinical outcome measures across patient groups in the United Kingdom Medical Cannabis Registry.

Medical 98
article thumbnail

The imperative of fridge-free vaccines

European Pharmaceutical Review

Over his career as a physician and scientist he published 108 papers and 49 patents. Injection Safety Fact Sheet. Since vaccines can now be reformulated to meet the relevant WHO guidelines, the route to a future of fridge-free vaccines is open. Available from: [link] q=US10821210B2. Internet] Médecins Sans Frontières. cited 2023July].

article thumbnail

How one pharma “family business” places patients first

pharmaphorum

There are many challenges in the development of therapies for rare diseases due to several unique factors, including small target patient populations, lack of long-term safety and efficacy data or natural history data, and often complex administration, dosing, and patient monitoring requirements,” Chiesi says.